The Technical Analyst
Global Blood [GBT]
Exchange: NASDAQ Global Select Sector: Healthcare Industry: Biotechnology
Global Blood Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.01% $68.49
/ 4 okt 2022 @ 16:00
| RATING 2022-10-05 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -14.08 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -14.08 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 67.60 - 69.38 ( +/- 1.30%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-10-05 | Perry Mark L | Sell | 5 600 | Stock Option (Right to Buy) |
| 2022-10-05 | Patrick Deval L | Sell | 5 600 | Stock Option (Right to Buy) |
| 2022-10-05 | Morrison Scott W | Sell | 5 600 | Stock Option (Right to Buy) |
| 2022-10-05 | Thompson Alexis A. | Sell | 3 600 | Restricted Stock Units |
| 2022-10-05 | Yarno Wendy L | Sell | 30 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -60.33 |
| Last 100 transactions |
| Buy: 278 284 | Sell: 1 075 911 |
Forecast:
01:40 - $75.39
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $68.49 (0.01% ) |
| Volume | 3.28 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GBT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GBT
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
Last 10 Buy Signals
Latest Press Releases
2022-08-31 12:00:00 - Press Release
Global Blood Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Global Blood Therapeutics, Inc. - Gbt
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of global blood therapeutics, inc. (gbt) (nasdaqgs: gbt) to pfizer inc. (nyse: pfe). under the terms of the proposed transaction, shareholders of gbt will receive $68.50 in cash for each share of gbt that they own. ksf is seeking to determine whether this consideration and the process that led to it are adequate,
2022-08-22 09:42:00 - Press Release
Shareholder Investigation Notice: Halper Sadeh Llp Investigates Aaww, Gbt, Cybe, Avlr
New york , aug. 22, 2022 /prnewswire/ -- halper sadeh llp, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: atlas air worldwide holdings, inc. (nasdaq: aaww)'s sale to funds managed by affiliates of apollo global management, inc. and affiliates of j.f. lehman & company and hill city capital for $102.50 per share in cash.
2022-08-15 09:00:00 - Press Release
Shareholder Investigation Notice: Halper Sadeh Llp Investigates Gbt, Avlr, Cybe, Sbcf
New york , aug. 15, 2022 /prnewswire/ -- halper sadeh llp, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: global blood therapeutics, inc. (nasdaq: gbt)'s sale to pfizer inc. for $68.50 per share in cash. if you are a global blood shareholder, click here to learn more about your rights and options.
2022-08-08 15:18:00 - Press Release
Shareholder Alert: Weiss Law Investigates Global Blood Therapeutics, Inc.
New york , aug. 8, 2022 /prnewswire/ -- weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of global blood therapeutics, inc. ("global blood" or the "company") (nasdaq: gbt), in connection with the proposed acquisition of the company by pfizer inc. (nyse: pfe). under the terms of the merger agreement, the company's shareholders will receive $68.50 in cash for each share of global blood common stock owned.
2022-08-08 06:45:00 - Press Release
Pfizer To Acquire Global Blood Therapeutics For $5.4 Billion To Enhance Presence In Rare Hematology
New york & south san francisco, calif.--(business wire)--pfizer inc. (nyse: pfe) and global blood therapeutics, inc. (gbt) (nasdaq: gbt) today announced the companies have entered into a definitive agreement under which pfizer will acquire gbt, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (scd). the acquisition complements and further enhances p
Latest News
2022-09-16 12:41:57 - Seeking Alpha
Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
After a slow first half, merger and acquisition deals are heating up for the remainder of 2022. In the efforts to boost its presence in rare hematology, Pfizer recently announced it is acquiring Global Blood Therapeutics for $5.4B.
2022-08-09 14:43:00 - Market Watch
Get ready for more merger mania in pharma sector the rest of the year
Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.
2022-08-09 12:47:23 - Zacks Investment Research
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.
2022-08-09 11:49:00 - Invezz
Pfizer is acquiring Global Blood Therapeutics
Pfizer Inc (NYSE: PFE) has executed a definitive merger agreement with Global Blood Therapeutics Inc (NASDAQ: GBT), whereby Pfizer will acquire the biopharmaceutical corporation dedicated to the delivery, development and discovery of life-changing medical treatment, Global Blood Therapeutics, for $5.4 billion, representing $68.50 per GBT share.
2022-08-09 06:18:49 - Proactive Investors
Pfizer to buy Global Blood Therapeutics for US$5.4bn
Pfizer Inc (NYSE:PFE) is to pay US$5.4bn in cash to acquire sickle cell disease drugmaker Global Blood Therapeutics, Inc (NASDAQ:GBT) (GBT) as the pharma major looks to leverage the booming revenue from its Covid-19 vaccine and treatment. Pfizer will pay US$68.50 per GBT share, which represents a 7.3% premium over Friday's closing price and nearly 43% over Thursday's closing price.
2022-08-08 14:51:34 - The Motley Fool
Why Global Blood Therapeutics Stock Was Trouncing the Market Today
The blood-disorder specialist sells itself in a deal with an enterprise value of around $5.4 billion.
2022-08-08 12:12:51 - InvestorPlace
GBT Stock Alert: Pfizer Is Officially Acquiring Global Blood Therapeutics
Source: ra2 studio/Shutterstock Last week, Global Blood Therapeutics (NASDAQ: GBT ) stock was thrust into the spotlight on reports of a potential buyout bid from Pfizer (NYSE: PFE ). Today, though, Pfizer has officially disclosed that it will buy the company for $5.4 billion.
2022-08-08 09:05:32 - Investors Business Daily
Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics
Pfizer inked a $5.4 billion deal Monday to buy Global Blood Therapeutics, confirming rumors that sent GBT stock skyrocketing last week. The post Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics appeared first on Investor's Business Daily.
2022-08-08 09:01:00 - Barrons
Pfizer Buys Global Blood Therapeutics. How the Deal Could Solve Pipeline Worries.
Pfizer said it would pay $68.50 per share for Global Blood Therapeutics which sells a sickle cell disease treatment called Oxbryta
2022-08-08 07:34:20 - Pulse2
Why Pfizer (PFE) Is Buying Global Blood Therapeutics (GBT) For $5.4 Billion
Pfizer Inc. (PFE) announced it is buying Global Blood Therapeutics (GBT) for $5.4 billion. This is why.